Bachen in Generics API

In our studies in collaboration with Novo Nordisk, we set out to identify environmentally benign solvents suitable for large-scale SPPS of peptide therapeutics at ambient temperature by assessing reagent solubility, resin swelling, amino acid coupling and Fmoc-removal efficiency in a collection of REACH compatible neat solvents and selected binary solvent mixtures. These studies have shown that binary solvent mixtures are indeed viable alternatives.

Microparticle formulation has been successfully applied in a number of commercial products containing peptides as APIs. The use of nanoparticles for delivering proteins and peptides are still in early stages of development. Discover how Bachem is part of this technology!

If you’re looking for news, product information and market trends from leading pharma companies, the CPHI-Online.com Company Showcases are a great resource for buyers who want to stay up to date, browse product portfolios and find the right partner. 

The Company Showcase profiles offer a library of free to access, downloadable content, including videos and webinars, reports, whitepapers and product brochures, from the Pharma suppliers and service providers you’d look to meet at our events.

The Molecular Hiving™️ technology is especially suitable for the synthesis of peptide ingredients for cosmetic products, as CMR solvents and reagents can entirely be avoided during the manufacturing process.

The Bachem Group (SIX: BANB) today announced measures and decisions designed to ensure that the global market is kept supplied with the active pharmaceutical ingredient Propofol from its Swiss production site in Vionnaz.

Learn about the Molecular HivingTM technology, it’s scalability and the substantial advantages regarding efficiency, CMR free synthesis of peptides and greener manufacturing.

Improving the sustainability in the CDMO industry is a multi-facetted approach covering environmental, economic and social tasks while having a strong focus on these areas where a company can make the highest impact. Bachem, the leading manufacturer of peptides and oligonucleotides is a good example for using this approach successfully. By innovating for better manufacturing the company could massively reduce greenhouse gas emissions and solvent consumptions: something that is also of utmost interest when searching for a partner for large-scale production of oligonucleotides and peptides.

As the world’s leading company in the development and production of peptides and oligonucleotides (TIDES), Bachem is a strategic partner for Biotechnology, Pharmaceuticals, Diagnostics, Cosmetics and Life Science research. We work in close collaboration with our customers to ensure the success of their ambitious product development programs.Innovation is one of our key success factors. We are not only producing peptides and oligonucleotides in large quantities in modern industrial production facilities; we are also automating our manufacturing processes wherever possible. We have set new standards in quality, increased efficiency and reduced solvent volumes. There is an increase in the therapeutic use of oligonucleotide-based drugs. The category is also expanding from rare diseases into chronic diseases, with the potential to make a huge difference to more lives. We identified this need for oligonucleotide therapeutics to address larger-scale patient populations and indications. This is driving our commitment and journey in oligonucleotide NCEs: we want to help build a new future.

Philipp Karbach, COO and CFO of AMW, spoke about his experience of working with Bachem: